

Metodesnitazene



Sample Type: Biological Fluid

Latest Revision: September 22, 2021

Date of Report: September 22, 2021

## **1. GENERAL INFORMATION**

IUPAC Name:	N,N-diethyl-2-[2-[(4-methoxyphenyl)methyl]benzimidazol-1- yl]ethanamine
InChI String:	InChI=1S/C21H27N3O/c1-4-23(5-2)14-15-24-20-9-7-6-8-19(20)22- 21(24)16-17-10-12-18(25-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3
CFR:	Not Scheduled (09/2021)
CAS#	1071546-40-1
Synonyms:	Desnitrometonitazene, Metazene
Source:	Montgomery County Coroner's Office (Ohio)

*Important Notes*: All identifications were made based on evaluation of analytical data (LC-QTOF-MS) in comparison to analysis of acquired reference material.

**Prepared By:** Alex J. Krotulski, PhD; Matthew Juhascik, PhD, F-ABFT; Kent Harshbarger, MD; Sara E. Walton, BS; Donna M. Papsun, MS, D-ABFT-FT; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT

#### 2. CHEMICAL DATA

Analyte	Chemical	Molecular	Molecular	Exact Mass
	Formula	Weight	Ion [M+]	[M+H] <sup>+</sup>
Metodesnitazene	$C_{21}H_{27}N_{3}O$	337.5	337	338.2227

#### **3. SAMPLE HISTORY**

To date, metodesnitazene was identified in one case in July 2021. The geographical and demographical breakdown is below:

Geographical Location:	Ohio (n=1)
<b>Biological Sample:</b>	Blood (n=1)
Date of First Receipt:	June 2021
Other Notable Findings:	Brorphine (n=1), 2-Methyl AP-237 (n=1), Bromazolam (n=1), Desalkylflurazepam (n=1), Fluoromethamphetamine (n=1), Fluoroamphetamine (n=1), Tramadol (n=1), Mitragynine (n=1)

### **4. BRIEF DESCRIPTION**

Metodesnitazene is classified as a novel opioid of the benzimidazole sub-class and is structurally dissimilar from fentanyl. Novel opioids have been reported to cause psychoactive effects similar to heroin, fentanyl, and other opioids. Novel opioids have also caused adverse events, including death, as described in the literature. Structurally similar compounds include etonitazene, metonitazene, and isotonitazene. Etonitazene and structurally related synthetic opioids were first synthesized and reported in the literature in the 1950s.<sup>1</sup> Data suggest that this group of analogues can have potency similar to or greater than fentanyl.<sup>2</sup> Recent *in vitro* data suggest that metodesnitazene is much less potent than fentanyl and approximately half the potency of morphine.<sup>3</sup> Metodesnitazene is not explicitly scheduled in the United States; however, etonitazene and isotonitazene are Schedule I substances.

### **5. ADDITIONAL RESOURCES**

1. Hunger, A; Kebrle, J; Rossi, A; Hoffmann, K. (1957) Synthesis of analgesically active benzimidazole derivatives with basic substitutions. *Experientia*, **13**, 400-401. https://link.springer.com/article/10.1007/BF02161116

2. Hoffmann, K; Hunger, A; Rossi, A. (3 May 1960). "Patent US2935514A – Benzimidazoles." https://patents.google.com/patent/US2935514A/en

 Vandeputte, MM; Van Uytfanghe, K; Layle, NK; St. Germaine, DM; Iula, DM; Stove, CP. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of "Nitazene" 2-Benzylbenzimidazole Synthetic Opioids. *ACS Chem. Neurosci.* 2021. https://pubs.acs.org/doi/10.1021/acschemneuro.1c00064

https://www.deadiversion.usdoj.gov/drug\_chem\_info/benzimidazole-opioids.pdf

https://www.caymanchem.com/product/30035/metodesnitazene-(hydrochloride)

### 6. QUALITATIVE DATA

#### 6.1 GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS)

Testing Performed At:	The Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation (Willow Grove, PA)
Sample Preparation:	Standard diluted in methanol
Instrument:	Agilent 5975 Series GC/MSD System
Standard:	Reference material for metodesnitazene (Batch: 0590970-1) was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). (https://www.caymanchem.com/product/30035/metodesnitazene- (hydrochloride))



## EI (70 eV) Mass Spectrum: Metodesnitazene (Standard)

# 6.2 LIQUID CHROMATOGRAPHY QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY (LC-QTOF-MS)

Testing Performed At:	The Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation (Willow Grove, PA)
Sample Preparation:	Liquid-liquid extraction (LLE)
Instrument:	Sciex TripleTOF® 5600+, Shimadzu Nexera XR UHPLC
Column:	Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm)
Mobile Phase:	A: Ammonium formate (10 mM, pH 3.0)
	B: Methanol/acetonitrile (50:50)
	Flow rate: 0.4 mL/min
Gradient:	Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min
Temperatures:	Autosampler: 15 °C

	Column Oven: 30 °C
	Source Heater: 600 °C
<b>Injection Parameters:</b>	Injection Volume: 10 µL
QTOF Parameters:	TOF MS Scan Range: 100-510 Da
	Precursor Isolation: SWATH® acquisition (27 windows)
	Fragmentation: Collison Energy Spread (35±15 eV)
	MS/MS Scan Range: 50-510 Da
<b>Retention Time:</b>	4.69 min
Standard Comparison:	<ul> <li>Reference material for metodesnitazene (Batch: 0590970-1) was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Analysis of this standard resulted in positive identification of the analyte in the extract as metodesnitazene, based on retention time (4.73 min) and mass spectral data.</li> <li>(https://www.caymanchem.com/product/30035/metodesnitazene-(hydrochloride))</li> </ul>

# Extracted Ion Chromatogram: Metodesnitazene (Biological Sample)



# TOF MS Spectra: Metodesnitazene (Biological Sample)



MS/MS Spectra: Metodesnitazene (Biological Sample)



### 7. FUNDING

Our program is supported in part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BX-0007, "Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive Substances (NPS)"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.